Gastrointestinal Cancer—Colorectal and Anal

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

4000 A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

Salvatore Siena, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav, et al. 

The abstract concludes: 
Overall, T-DXd 6.4 mg/kg q3w demonstrated remarkable activity in pts with HER2-expressing mCRC refractory to standard therapies, with a safety profile consistent with previous results. ILD is an important risk and requires careful recognition and intervention. Clinical trial information: NCT03384940.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Scott Kopetz, Axel Grothey, Eric Van Cutsem, et al.
 
The abstract concludes: 
The updated analysis of the BEACON CRC study confirmed that encorafenib + cetuximab with or without binimetinib improved OS and ORR in previously treated pts with BRAF V600E mCRC compared with standard chemotherapy. Clinical trial information: NCT02928224.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4002 First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

Sara Lonardi, Marta Schirripa, Federica Buggin, et al.
 
The abstract concludes: 
Large prospective randomized studies in molecularly selected elderly mCRC are feasible with multicenter collaborative efforts. Primary EP was met in both treatment arms. 5FU/LV plus panitumumab for up to 12 cycles followed by panitumumab maintenance until PD might be a reasonable option in elderly mCRC patients with RAS/BRAF wt tumors deserving further investigations in phase III trials. Clinical trial information: NCT02904031.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4003 Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, et al. 
 
The abstract concludes: 
The addition of celecoxib to standard chemotherapy did not significantly improve DFS or OS. Clinical trial information: NCT01150045.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Alberto F. Sobrero, Thierry Andre, Jeffrey A Meyerhardt, et al.
 
The abstract concludes: 
5y OS rate reported in IDEA trials was higher than historical rates, regardless of duration of therapy. While overall survival in IDEA did not meet prior statistical assumptions for NI in overall population, the 0.4% difference in 5y OS should be placed in clinical context. OS and 5y DFS results continue to support the use of 3m adjuvant CAPOX for the vast majority of stage III colon cancer pts. This conclusion is strengthened by the substantial reduction of toxicities, inconveniencies and cost associated with shorter treatment duration. Clinical trial information: NCT01150045; 2009-010384-16; NCT00749450; ISRCTN59757862; 2007-003957-10; UMIN000008543; 2007-000354.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4005 A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study. 

Yukihide Kanemitsu, Yasuhiro Shimizu, Junki Mizusawa, et al.
 
The abstract concludes: 
DFS did not correlate with OS for LM. Postoperative chemotherapy with mFOLFOX6 improves DFS but worsens OS over surgery alone due to more deaths after recurrence in the CTX arm. Adjuvant mFOLFOX is not beneficial to patients after hepatectomy for LM. Clinical trial information: UMIN000000653.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Geke Hospers, Renu R. Bahadoer, Esmee A. Dijkstra, et al. 
 
The abstract concludes: 
A lower rate of DrTF, as a result of a lower rate of distant metastases, in high-risk LARC patients can be achieved with preoperative short-course radiotherapy, followed by chemotherapy and TME than by conventional chemoradiotherapy. In addition, the high pCR rate, achieved with the experimental treatment regimen can contribute to organ preservation. This treatment can be considered as a new standard of care. Clinical trial information: NCT01558921.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Thierry Conroy, Najib Lamfichekh, Pierre-Luc Etienne, et al.
 
The abstract concludes: 
Neoadjuvant mFOLFIRINOX plus CRT is safe, and significantly increased ypCR rate, DFS and MFS. OS data are not mature. Clinical trial information: NCT01804790.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Julio Garcia-Aguilar, Sujata Patil, Jin K. Kim, et al. 
 
The abstract concludes: 
A WW strategy for patients with locally advanced rectal cancer that achieve a clinical complete response to TNT results in organ preservation for a high proportion of patients without compromising survival. Up-front CRT followed by consolidation chemotherapy resulted in a numerically higher WW rate compared to induction chemotherapy followed by CRT. Clinical trial information: NCT02008656.